Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 6/2005 | Cierra | Funding Round | 21M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 10/2003 | Cotherix | Series C | 55M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 8/2009 | Barosense | Series D | 27M |
| 7/2013 | Alcresta | Series B | 10M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 6/2003 | Xoft | Series B | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 4/2007 | Xoft | Series D | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 3/2020 | Amunix | Series A | 0 |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 4/2008 | Stromedix | Series B | 25M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 3/2006 | PowerVision | Series A | 2M |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 2/2021 | Seraxis | Series C | 40M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 2/2007 | Pivot Medical | Series A | 2M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 12/2003 | FlowCardia | Series B | 12M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 3/2009 | Stemgent | Series B | 14M |
| 9/2002 | Glaukos | Series A | 10M |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 3/2021 | Amunix | Series B | 117M |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 1/2014 | PowerVision | Series D | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 1/1996 | Corixa | Venture Round | - |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 8/2007 | FlowCardia | Series C | 0 |
| 6/2006 | PatientKeeper | Series E | 0 |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 1/2005 | PowerVision | Series A | 4.4M |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 1/1993 | VIVUS | Venture Round | - |
| 4/2012 | Alcresta | Series A | 10M |
| 3/2007 | Stromedix | Series A | 1M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 1/2006 | Xoft | Series C | 0 |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 5/2016 | Aptinyx | Series A | 0 |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 7/2010 | BARRX Medical | Series D | 15M |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 12/2004 | Barosense | Series B | 6.2M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 10/2005 | EBR Systems | Series B | 21M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 1/2000 | Simpata Inc | Series B | 20M |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 1/1991 | Tularik | Funding Round | - |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/1996 | ViroPharma | Funding Round | - |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 5/2007 | CVRx | Series D | 65M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 7/2011 | PowerVision | Series C | 24M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 12/2007 | Barosense | Series C | 11.2M |
| 11/2017 | Mavupharma | Series A | 0 |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 4/2001 | Fast Track | Series C | 0 |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 11/2020 | Inipharm | Series A | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 3/2019 | Scout Bio | Series B | 20M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 12/2007 | PowerVision | Series B | 20M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2008 | EBR Systems | Series C | 35M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2008 | CVRx | Series E | 0 |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 9/2019 | Passage Bio | Series B | 110M |
| 1/2019 | Sojournix | Series C | 44M |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 8/2008 | Glaukos | Series D | 35M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 8/2000 | PatientKeeper | Series B | 0 |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 8/2008 | Calibra Medical | Series B | 35M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
